Tobacco-free oral nicotine pouches (such as Zyn brand) are a less harmful alternative to combustible tobacco (cigarette/cigarillo/little cigar) smoking. Pouches, however, contain nicotine, and addictive substance that is not risk-free. The present study is evaluating how well nicotine pouches, at different nicotine levels, help people switch away from smoking combustible tobacco. People who smoke will be asked to answer questions about their tobacco product use and provide breath samples and cheek swab samples at an in-person visit to MUSC Charleston. Participants will then be provided with a 28-day supply of nicotine pouches, and will be asked to switch from smoking to pouches over the course of 4 weeks. Finally, participants will complete a final visit at MUSC, and will answer more questions about their tobacco use 1-month later.

This study aims to determine if photo biostimulation with Nd-YAG laser improves wound healing following tooth extraction and alveolar ridge preservation. The impact of laser treatment on wound healing will be evaluated by levels of salivary inflammatory biomarkers, gingival wound size, and surveying for pain reduction and patient satisfaction. The intervention group will receive standard-of-care extraction and alveolar ridge preservation with adjunct Nd-YAG laser photobiostimulation on days 1, 3, and 7, while the control group will receive the standard-of-care extraction and alveolar ridge preservation only.

The study is for subjects that are undergoing knee surgery to repair and reconstruct the ligaments and tendons in the knee. Data will be collected to evaluate the continued safety and effectiveness of the screws and anchors that are used during the surgery to do the repair and reconstruction of the ligaments and tendons in the knee. There are six visits over a two-year time period that will be conducted during your standard of care visits with the doctor. During those visits outcome data will be collected via questionnaires. The study is designed to collect real world data from the general population on products that are cleared for sale in the U.S.

This study is being conducted at approximately 150 research centers worldwide and is expected to enroll approximately 675 pediatric subjects in total with moderately to severely AD. This study will have 2 cohorts, a Randomized Cohort, and a Dupilumab-Inadequate Responder / Dupilumab Medically Inadvisable Cohort. The study comprises a 35-day Screening Period; a 16-week, open-label, efficacy assessor blinded study treatment period for the subjects in the randomized cohort; an open-label period up to Week 160 for subjects in the upadacitinib study treatment arms across both cohorts (Randomized Cohort and Dupi-IR/Dupilumab Medically Inadvisable Cohort); an open label period up to Week 52 for subjects in the dupilumab arm; and a 30-day Follow up Visit/call after the last dose is administered for upadacitinib or dupilumab.

This is a study to learn more about the use of a study medicine for the treatment of Idiopathic Hypersomnia (IH). The total duration of the study is approximately 3 1/2 months. Men and women between the ages of 18-75, with a primary diagnosis of IH, may be eligible.

This study will determine if people on oral anti-cancer treatment who have these symptoms monitoring calls plus other support will have less severe symptoms and less visits to the hospital, emergency room or urgent care compared to only symptom monitoring calls. The patients are expected to participate in this study for a minimum of 12 weeks. During the trial patients will receive a telephone call to monitor symptoms.

We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems. Dapagliflozin is an approved drug to treat patients with heart failure, chronic kidney disease and type 2 diabetes mellitus.

Rates of heavy episodic drinking (HED) among military veterans are almost double that of the general population. Veterans also experience more serious negative health consequences of HED, including high-risk behaviors such as aggression. Research shows there is a link between HED and aggression. However, no programs exist to reduce alcohol-related aggression among veterans. The purpose of this study is to examine the feasibility and acceptability of adapting a current therapy - Managing Emotions to Reduce Aggression (MERA) - to include alcohol-focused Motivational Interviewing plus Feedback (MIF). We will use a brief, four session protocol that includes an hour of talk therapy, plus completion of surveys at each of the four sessions.

The research is being done to determine if an investigational drug called "TS23" is safe and effective for the treatment of patients with an ischemic stroke that do not meet the criteria for standard treatments to remove the clot. The best dose of TS23 for these patients is unknown. Prior studies have shown that TS23 works without increasing safety concerns.

The goal of this study is to get the highest possible quality of life restuls for individuals suffering lower-limb impairment after suffering a stroke. This will be done by examining three different modern carbon fiber ankle-foot orthosis (AFO) options targeting the rehabilitation of individuals post-stroke. The study seeks to achieve the best AFO prescription that maximizes the mobility and satisfaction of the particpant.